23andMe, the genetics startup that has repeatedly captured the general public creativeness after which confronted practically deadly enterprise challenges, introduced Monday that it will halt its efforts to develop new medicines and lay off 40% of its workforce, focusing as an alternative on promoting genetic checks to customers and utilizing the ensuing information for analysis.
In closing its therapeutics division and shedding 200 individuals, 23andMe ended an audacious guess it made practically a decade in the past — that it might use the genetic information it had collected not solely to help drug corporations however to develop into one itself.
“We’re taking these tough however needed actions as we restructure 23andMe and give attention to the long-term success of our core client enterprise and analysis partnerships,” mentioned Anne Wojcicki, 23andMe’s CEO, co-founder, and chair of the board. “I wish to thank our workforce for his or her arduous work and dedication to our mission. We’re absolutely dedicated to supporting the workers impacted by this transition.”
This text is unique to STAT+ subscribers
Unlock this text — plus each day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
View All Plans
